ストックスクリーナーアプリを入手
9.21
2.33%
0.21
プレマーケット:
9.45
0.24
+2.61%
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday - MarketBeat
Kyverna appoints Nadia Dac as chief commercial officer By Investing.com - Investing.com Australia
Kyverna appoints Nadia Dac as chief commercial officer - Investing.com UK
Kyverna Therapeutics Appoints Nadia Dac as Chief Commercial Officer to Lead Launch of miv-cel for Stiff Person Syndrome and Neuroimmunology Expansion - Minichart
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth - TipRanks
Kyverna brings in a 30-year launch veteran for its commercial push - Stock Titan
Kyverna (NASDAQ: KYTX) hires Nadia Dac as CCO with 300,000-share option - Stock Titan
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer - Yahoo Finance
AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX stock soars after hours: What’s driving the rally? - MSN
KYTX Stock Price, Quote & Chart | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
JP Morgan initiated coverage on Kyverna Therapeutics with a new price target - Quantisnow
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy - MSN
Kyverna Therapeutics (KYTX) stock surges 24% after hours: Why is it moving? - MSN
KYTX Price Today: Kyverna Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA - MarketBeat
Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buy - Investing.com
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet - Seeking Alpha
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis - Seeking Alpha
Walking the talk, Kyverna phase II stiffens miv-cel CAR T case - BioWorld News
Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap UpShould You Buy? - MarketBeat
Kyverna’s Miv-cel Achieves Breakthrough Results in Stiff Person Syndrome, Paving Way for First Approved Therapy - Minichart
Kyverna Therapeutics Unveils Transformative CAR T Therapy Data for Stiff Person Syndrome and Generalized Myasthenia Gravis at AAN 2026 - Minichart
KYTX: miv-cel delivers unprecedented, durable efficacy and safety in SPS and GMG, supporting strong launch potential - TradingView
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data - TipRanks
KYTX: Miv-cel achieved durable, drug-free remission and robust clinical benefit in SPS and gMG - TradingView
Miv-cel data position Kyverna (NASDAQ: KYTX) for SPS BLA and gMG Phase 3 - Stock Titan
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome - TipRanks
KYTX: Miv-cel showed robust, durable efficacy and safety in SPS, with all patients off chronic immunotherapies - TradingView
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving? - Benzinga
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics announces positive primary analysis results from KYSA-8 trial of Miv-Cel in SPS - marketscreener.com
Kyverna Therapeutics Announces Positive Primary Analysis Results From KYSA-8 Trial Of Miv-Cel In SPS - TradingView
Kyverna Therapeutics Reports Positive Trial Results for Miv-cel in Stiff Person Syndrome, Highlighting Potential to Transform Treatment Paradigm - Quiver Quantitative
Miv-cel delivers significant SPS gains in Kyverna (NASDAQ: KYTX) registrational trial - Stock Titan
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting - Yahoo Finance
KEI Comments on Exclusive License to Kyverna Therapeutics - Knowledge Ecology International
Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.2%Should You Sell? - MarketBeat
Kyverna Therapeutics: Strengthened Buy Rating on Robust Miv-cel Data and Reduced Regulatory Risk in gMG - TipRanks
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):